Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | C1S | P09871 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239016 | 0.98 | F2 (0.44) | BLMKMT2AC1SPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL29008442 | 0.82 | BLM (0.57) | BLMKMT2AC1SPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL28555632 | 0.82 | BLM (0.57) | BLMKMT2AC1SPRSS1PRSS2 | |
| SCHEMBL7863179 | 0.80 | ALDH1A1 (0.41) | BLMKMT2AC1SPRSS1PRSS2 | |
| SCHEMBL8887730 | 0.80 | TSHR (0.53) | KMT2AMIFMEN1POLBALDH1A1 | |
| SCHEMBL10495281 | 0.79 | F2 (0.55) | BLMKMT2AC1SPRSS1PRSS2 | |
| SCHEMBL6957591 | 0.77 | ALDH1A1 (0.40) | KMT2AL3MBTL1NPC1RAB9AMIF | |
| Hydrochloric Acid SCHEMBL4100040 | 0.76 | METAP2 (0.56) | BLMKMT2ARECQLL3MBTL1NPC1 | |
| Hydrochloric Acid SCHEMBL4383251 | 0.76 | METAP2 (0.56) | BLMKMT2ARECQLL3MBTL1NPC1 | |
| SCHEMBL27978394 | 0.76 | ALDH1A1 (0.42) | KMT2ANPC1RAB9AMIFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117003738-A | Imidazole spiro compound and synthesis method thereof | 湘潭大学 | 2023-11-07 | — | — | CN | claimed |
| JP-61167671-A | — | — | None | — | — | JP | disclosed |
| US-20260042791-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-12 | — | — | US | disclosed |
| US-12281129-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-04-22 | — | — | US | disclosed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| CN-117003738-A | Imidazole spiro compound and synthesis method thereof | 湘潭大学 | 2023-11-07 | — | — | CN | disclosed |
| US-11737349-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220402953-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSITY DISPLAY CORPORATION (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050065153-A1 | Novel heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1399447-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030139415-A1 | Novel heterocycles 3 | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2002098879-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| JP-S61167671-A | 4-(5-ALKYLPYRIMIDIN-2-YL)BENZOIC ACID-4'-CYANO-3'-HALOGENOPHENYL | CHISSO CORP | 1986-07-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139415-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | GAA 3483/4885BLM 345/4885KMT2A 3246/4885 |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | GAA 740/4885BLM 2810/4885KMT2A 377/4885 |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | GAA 2921/4885BLM 2881/4885KMT2A 2767/4885 |
| US-12281129-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | GAA 1811/4885BLM 1713/4885KMT2A 3332/4885 |
| US-11737349-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OTC | GAA 2513/4885BLM 1788/4885KMT2A 2138/4885 |
| US-20260042791-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, GLRA1, MSL1 | GAA 4150/4885BLM 2106/4885KMT2A 3463/4885 |
| US-20050065153-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | GAA 3483/4885BLM 345/4885KMT2A 3246/4885 |
| US-20220402953-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | GAA 1811/4885BLM 1713/4885KMT2A 3332/4885 |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | GLI1, GLI2, SHH | GAA 740/4885BLM 2810/4885KMT2A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.